Oura Ring Gen 4 sensor data, not clinical measurementsN=1 case study, not validated for clinical decisionsHEV diagnosed Mar 18; Day 109 post-ruxolitinibMore
Consumer wearable data can support exploratory review only. The HEV diagnosis, temporally confounded with treatment start, remains a material confounder.

Weekly Tracker

2026-06-26 to 2026-07-02
GREEN
On Track
9
Metrics in normal range
AMBER
Watch
3
Borderline or declining
RED
Alert
0
Needs attention
IMPROVING
In range
5
Week-over-week
DECLINING
Watch
3
Week-over-week

Doctor Summary - Week of 2026-06-26 to 2026-07-02

  • Temp Deviation improved -50.6% to 0.12 °C
  • Steps improved +32.7% to 3692 steps
  • HRV (RMSSD) declined -6.1% to 25.5 ms -- monitor
  • Day 108 on ruxolitinib (started 2026-03-16)
METRICS

Metric Details

HRV (RMSSD)
25.5ms
↓ -6.1%Last week: 27.1 ms
Lowest HR
57.8bpm
↔ -0.5%Last week: 58.1 bpm
Average HR
66.7bpm
↔ +0.1%Last week: 66.6 bpm
Sleep Duration
7.4h
↑ +8.1%Last week: 6.8 h
Deep Sleep
1.4h
↓ -5.6%Last week: 1.5 h
REM Sleep
1.4h
↑ +10.6%Last week: 1.3 h
Sleep Efficiency
84%
↔ +3.0%Last week: 82 %
Readiness Score
81pts
↑ +5.0%Last week: 77 pts
Recovery Index
69pts
↓ -5.9%Last week: 73 pts
Steps
3692steps
↑ +32.7%Last week: 2781 steps
Temp Deviation
0.12°C
↑ -50.6%Last week: 0.24 °C
Breath Rate
15.9brpm
↔ +0.5%Last week: 15.8 brpm
RUXOLITINIB

Ruxolitinib Progress

Day 108 on ruxolitinib (started 2026-03-16)

MetricPre-Rux BaselineThis WeekChange
HRV (RMSSD)11.7 ms25.5 ms↑ +117.7%
Lowest HR73.0 bpm57.8 bpm↓ -20.8%
Average HR80.5 bpm66.7 bpm↓ -17.1%
Sleep Duration6.0 h7.4 h↑ +23.2%
Deep Sleep1.0 h1.4 h↑ +41.8%
REM Sleep0.8 h1.4 h↑ +64.9%
Sleep Efficiency79 %84 %↑ +6.3%
Readiness Score69 pts81 pts↑ +17.4%
Recovery Index63 pts69 pts↑ +9.1%
Steps2540 steps3692 steps↑ +45.3%
Temp Deviation0.21 °C0.12 °C↓ -41.7%
Breath Rate14.0 brpm15.9 brpm↑ +14.0%